

# NIH Public Access

Author Manuscript

J Org Chem. Author manuscript; available in PMC 2006 July 21.

Published in final edited form as: J Org Chem. 2005 August 19; 70(17): 6842–6847.

# Complete Stereochemistry of Neamphamide A and Absolute Configuration of the $\beta$ -Methoxytyrosine Residue in Papuamide B

Naoya Oku<sup>†</sup>, Ravi Krishnamoorthy<sup>‡</sup>, Alan G. Benson<sup>‡</sup>, Robert L. Ferguson<sup>‡</sup>, Mark A. Lipton<sup>‡</sup>, Lawrence R. Phillips<sup>§</sup>, Kirk R. Gustafson<sup>\*,†</sup>, and James B. McMahon<sup>†</sup> †Molecular Targets Development Program, CCR, NCI. Molecular Targets Development Program, Center for Cancer Research, National Cancer Institute, Building 1052, Room 121, Frederick, Maryland 21702-1201

‡Purdue University. Department of Chemistry, Purdue University, West Lafayette, Indiana 47907-2084

§Biological Testing Branch, DTP, NCI. Biological Testing Branch, Developmental Therapeutics Program, National Cancer Institute, Building 1047, Room 5, Frederick, MD 21701-1201

# Abstract

The absolute stereochemistry of the three unresolved structural components in neamphamide A (1) was determined to be (R)- $\beta$ -methoxy-L-tyrosine, (2R,3R,4S)-4-amino-7-guanidino-2,3-dihydroxyheptanoic acid, and (2R,3R,4R)-3-hydroxy-2,4,6-trimethylheptanoic acid. Stereochemical assignments were made by chemical degradation of 1, derivatization of the resulting products, and then spectroscopic and chromatographic comparison of the derivatives with synthetically prepared standards. Using the same analytical protocol developed for 1, the  $\beta$ -methoxytyrosine residue in papuamide B (2) was found to be (R)- $\beta$ -methoxy-D-tyrosine. This represents a rare example of divergent stereochemistry in an unusual amino acid residue that is present in two closely related classes of peptides.

# Introduction

A series of potent HIV inhibitory cyclic depsipeptides have recently been described from a number of marine sponges. Peptides in this family include neamphamide A (1) from *Neamphius huxleyi*,<sup>1</sup> the callipeltins from *Callipelta* sp.,<sup>2</sup> and the papuamides from *Theonella* sponges.<sup>3</sup> In addition to antiviral activity, these compounds have been reported to exhibit potent antifungal, cytotoxic, and sodium ionophore properties.<sup>4</sup> Distinguishing structural characteristics of this family of peptides include a preponderance of unusual amino acid residues and unique N-terminal polyketide derived moieties. The novel structural features and diverse biological effects of these peptidic metabolites have generated considerable interest among synthetic chemistry groups. As a result, syntheses of structural subunits such as 3,4-dimethylglutamine (3,4-diMeGln),<sup>5</sup> 4-amido-7-guanidino-2,3-dihydroxyheptanoic acid (3, Agdha),<sup>6</sup> -and 3-hydroxy-2,4,6-trimethylheptanoic acid (4, Htmha)<sup>7</sup> have been described. These efforts provided essential building blocks for use in total synthesis of the parent peptides and they also helped to unambiguously define the absolute stereochemistry of several key chiral centers. However, synthetic efforts to prepare the intact natural products have been hampered by unresolved questions concerning the stereochemistry of the  $\beta$ -methoxytyrosine (5,

<sup>\*</sup>To whom correspondence should be addressed. Tel: (301)-846-5391. Fax: (301)-846-6919.

**Supporting Information Available**. Experimental procedures, <sup>1</sup>H NMR spectra of **3** at 0 h and 24 h in CD<sub>3</sub>OD, positive ESI-MS spectra of **3** obtained before and after 60 h-NMR experiments, <sup>1</sup>H NMR, gHSQC, and 1D gNOESY spectra of **7** in CD<sub>3</sub>OD, <sup>1</sup>H NMR, gHSQC, and 1D gNOESY spectra of **8** in D<sub>2</sub>O, <sup>1</sup>H NMR and gHSQC spectra of **4** from **1** and synthetic (2R,3R,4R)-**4**, GC-MS analysis of **16** derived from **1** and **2**.

 $\beta$ OMeTyr) residues which occur throughout this family of peptides. While stereoselective syntheses of all four diastereomers of **5** has been reported,<sup>8</sup> the absolute stereochemistry of this residue in the natural peptides was never established. Decomposition of **5** during acid hydrolysis of the parent peptide prevented the successful application of standard techniques such as Marfey's analysis.<sup>9</sup> In the original report of neamphamide A (**1**), the chirality of the Agdha, Htmha and  $\beta$ OMeTyr residues was left undefined. Described herein is the first complete stereochemical assignment of neamphamide A (**1**) and a general method for determining the absolute stereochemistry of  $\beta$ OMeTyr (**5**) residues in other peptides. This technique was also used to unambiguously define the stereochemistry of the same residue in papuamide B (**2**), and the results of these analyses should help focus the synthetic efforts underway to prepare the parent peptides.

#### **Results and Discussion**

Our prior studies had established the absolute stereochemistry of 9 amino acid residues of neamphamide A (1) as D-Arg, L-Leu, D- and L-Asn, L-NMeGln, L-homoproline, D-allo-Thr (two residues), and (3S,4R)-3,4-diMe-L-Gln. In addition, C4 of the Agdha (3) moiety was assigned a S-configuration by chemical degradation involving diol-cleavage, oxidative work up, and acid hydrolysis, followed by Marfey's analysis of the resulting arginine subunit.<sup>1</sup> In the current study, a synthetic standard of 3 with defined stereochemistry was available for comparative purposes,<sup>6</sup> but direct application of Marfey's method to the peptide hydrolysate to determine the stereochemistry at C2 and C3 proved unsuitable. The L-FDAA derivative of **3** had poor retention on reversed-phase chromatography packings and unacceptable peak broadening in the LC-MS analysis. Accordingly, the  $\gamma$ -amino acid **3** was isolated from the hydrolysate of 1 and converted into cyclic derivatives appropriate for NMR based configurational analysis at C2, C3, and C4. Compound 1 was hydrolyzed in 6N HCl (107°C, 18.5 h), defatted with EtOAc, and the resulting aqueous hydrolysate was purified by anionand then cation-exchange chromatography to give a mixture of **3** and Arg. While dissolved in CD<sub>3</sub>OD for NMR studies, compound **3** was gradually converted to the trideuteriomethyl ester derivative **6**. This transformation was evidenced from <sup>1</sup>H resonances at  $\delta$  4.03 (H3 of **3**) and 4.37 (H2 of 3), which diminished in intensity while resonances at  $\delta$  4.03 (H3 of 6) and 4.35 (H4 of 6) emerged and grew with time (Supporting Information). Positive ion ESI-MS data obtained before and after the NMR experiments showed the appearance of a dominant ion peak at  $m/z 252^{10}$  and complete loss of the original peak at m/z 235 (Supporting Information), which supported the conversion of 3 to the methyl ester 6. Preparation of the acetonide of 6 with 2,2dimethoxypropane and PPTS in DMF exclusively yielded the 2,3-O,O-isopropylidene derivative 7.<sup>11</sup> In 1D gNOESY experiments, selective irradiation of one of the acetonide methyl signals at  $\delta$  1.36 excited the two oxymethine protons at  $\delta$  4.65 (H2) and  $\delta$  4.74 (H3). No NOE enhancement was observed with these protons upon irradiation of the other methyl group at  $\delta$  1.40, thus indicating H2 and H3 were on the same face of the dioxolane ring. To correlate the *erythro*-diol moiety at C2-C3 with the S-configuration of neighboring C4, 7 was treated with 2N HCl to recover 3, which was then refluxed in H<sub>2</sub>O for 60 h to achieve partial conversion into Agdha  $\gamma$ -lactam (8, 63% yield).<sup>12</sup> The coupling constants observed between protons on the lactam ring of 8 were  $J_{H2,H3}$ =4.7-4.9 Hz and  $J_{H3,H4}$ =3.6 Hz. This combination of couplings was compared to the reported values for four similarly functionalized synthetic  $\gamma$ -lactams (Scheme 1), <sup>13</sup> and they were only compatible with the (2R,3R,4S)-isomer. Further support for this stereochemical assignment was provided by mutual NOE interactions between H2 ( $\delta$  4.31) and H4 ( $\delta$  3.52) in a 1D gNOESY experiment. Thus, the configuration of **3** in the peptide 1 was determined to be (2R, 3R, 4S), which is consistent with the stereochemistry previously assigned to the Agdha residue in callipeltin A (9).<sup>2</sup>

The EtOAc extract of the acid hydrolysate of neamphamide A (1) contained free Htmha (4) as the major constituent. Careful interpretation of the  ${}^{1}$ H, gCOSY, and gHSQC spectra of the

EtOAc extract allowed assignment of the NMR signals from **4**, and these were compared with published data for four synthetic diastereomers of this fatty acid<sup>7d</sup> including (2R,3R,4R)-, (2S,3R,4R)-, (2S,3R,4R)-, and (2R,3R,4S)-**4**. <sup>1</sup>H NMR chemical shifts for **4** showed the greatest similarity to those for the (2R,3R,4R)-isomer, which indicated that the hydroxy acid recovered from the hydrolysis of **1** had to have either (2R,3R,4R) or (2S,3S,4S)-stereochemistry. To establish the absolute stereochemistry of these chiral centers, **4** from **1** was condensed with (S)-(+)-phenylglycine methyl ester (PGME)<sup>14</sup> and the product was subjected to LC-MS analysis. To prepare appropriate chromatographic standards, synthetic (2R,3R,4R)-**4** was reacted either with (S)-(+)- or (R)-(-)-PGME to obtain (2R,3R,4R)-**4** (S)-(+)-PGME amide and (2R,3R,4R)-**4** (R)-(-)-PGME amide. The latter derivative is chromatographically equivalent to the (S)-(+)-PGME amide of enantiomeric (2S,3S,4S)-**4** when chromatographed on an achiral support. The reversed-phase HPLC retention time for the PGME amide, thus verifying a (2R, 3R,4R) configuration for the subunit **4** in **1**, which was the same as that established for callipeltin A (**9**).<sup>7c</sup>, 7d

The synthetic procedure we developed to obtain reference standards of the four diastereomers of  $\beta$ OMeTyr (5) was based on the stereoselective synthesis of  $\beta$ -hydroxytyrosine reported by Boger.<sup>15</sup> An adaptation of Boger's procedure (Scheme 2), in which a partially diastereoselective addition of a metallated Schöllkopf reagent<sup>16</sup> (10) to 4benzyloxybenzaldehyde formed the two key stereogenic centers, afforded roughly a 1:1 mixture of two epimeric carbinols (11a,b). Chromatographic separation afforded 11a and 11b in stereochemically pure form. Spectral correlation with Boger's published spectra<sup>15</sup> permitted the assignment of configuration for each isomer. Methylation of the hydroxyl group and hydrolysis of the bis-lactim ether using mild acid afforded stereochemically pure (S)- and (R)-O-benzyl-L-tyrosine methyl esters (13a and 13b, respectively). Transesterification with allyl alcohol mediated by titanium tetraisopropoxide afforded the allyl esters 14a and 14b in 15 and 17% overall yields, respectively, from 4-benzyloxybenzaldehyde. Repetition of this procedure using the enantiomeric Schöllkopf reagent ent-10 afforded ent-14a and ent-14b in stereochemically pure form and in comparable yields. Treatment of the allyl esters 14a, 14b, ent-14a, and ent-14b with 0.2 N LiOH and subsequent hydrogenolysis on Pd(OH)<sub>2</sub> gave (S)βOMe-L-Tyr, (R)-βOMe-L-Tyr, (R)-βOMe-D-Tyr, and (S)-βOMe-D-Tyr, respectively, in quantitative yields.

In a stability test of 5 using the (S)- $\beta$ OMe-D-Tyr as a model, the amino acid tolerated 2 N HCl but partially decomposed when kept in 6 N HCl for 1.5 h at room temperature to give a burgundy-colored residue that was insoluble in water but soluble in MeOH. We presumed that acid catalyzed decomposition of the  $\beta$ OMeTyr residue might involve elimination of the  $\beta$ methoxy group followed by a nucleophilic attack to form condensation products as illustrated in Scheme 3. In an initial effort to avoid decomposition of this residue during hydrolysis, 1 was fully protected with Cbz and then hydrolyzed in alkaline media, e.g. 1 N or 2.5 N KOH-MeOH, to liberate N-Cbz- $\beta$ OMeTyr or N,O-bis(Cbz)- $\beta$ OMeTyr. However, the reaction was inconsistent in yield and detection of the desired products by LC-MS was not successful. Development of an alternative approach to circumvent these problems was clearly warranted. Therefore, the authentic standards of 5 were converted into 3-methoxyaspartic acid (OMeAsp) by oxidation with RuCl<sub>3</sub>-NaIO<sub>4</sub>(CCl<sub>4</sub>-MeCN-0.1N sodium phosphate buffer=2:2:3, pH 7.6), 17 and then isolated as their N-Cbz derivatives by treating the dried reaction mixtures with CbzCl followed by solvent-partitioning (Scheme 4). LC-MS analysis of the N-Cbz-OMeAsp products resulted in very broad, low intensity peaks, so the amino acid derivatives were methylated with TMS-diazomethane to give 15. While the peak shape and peak intensity of the dimethyl ester 15 was improved, it was not possible to resolve the four diastereotopic standards by HPLC, even when they were chromatographed on chiral supports (Regis Sumipax OA-3100 L-Val and Regis Pirkle D-phenylglycine). Successful separation of the four

diastereomers was ultimately achieved by replacing the Cbz group with TFA (Scheme 4)<sup>18</sup> and then analyzing the products by GC-MS on a Chirasil-L-Val capillary column. Although a molecular ion for *N*-TFA-OMeAsp dimethyl ester (**16**) was not observed under the GC-MS conditions, diagnostic fragment ions, e.g. m/z 196 [M- ·COOMe-MeOH]<sup>+</sup> and m/z 103 [C (OMe)COOMe]<sup>+</sup> (Figure 1), were used to identify each diastereomer which eluted in the order (2*R*,3*R*), (2*S*,3*S*), (2*R*,3*S*), and (2*S*,3*R*) with satisfactory peak separation ( $t_R$ : 15.5, 15.8, 16.4, and 16.7 min, respectively).

With appropriate standards in hand, stereochemical assignments of the  $\beta$ OMeTyr residues in **1** and **2** were initiated. The peptides were oxidized with RuCl<sub>3</sub>-NaIO<sub>4</sub>, hydrolyzed in 6 N HCl (110 °C, 6 h), and the hydrolysates were successively derivatized with HCl-MeOH and TFAA to provide GC-MS samples. The extracted ion traces for the m/z 196 and m/z 103 fragment ions from *N*-TFA-OMeAsp dimethyl ester (**16**) both clearly showed the elution of (2*S*, 3*S*)-**16** ( $t_R$ 15.8 min) from the oxidative degradation product of **1** and (2*R*,3*S*)-**16** ( $t_R$ 16.4 min) from that of **2** (Supporting Information). The complete oxidation, hydrolysis, derivatization and analysis sequence was repeated with both parent peptides, and the results were consistent each time. This allowed assignment of a (*R*)- $\beta$ OMe-L-Tyr residue in **1** and a (*R*)- $\beta$ OMe-D-Tyr residue in **2**.



In conclusion, we have defined the absolute configuration of the hydroxy acid moiety and the two unusual amino acid residues in neamphamide A (1) as (2R,3R,4R)-Htmha, (2R,3R,4S)-Agdha and (R)- $\beta$ OMe-L-Tyr, respectively. This is the first time the complete stereostructure has been assigned for a member of this family of anti-HIV sponge depsipeptides. In addition, a new analytical procedure was established to determine the absolute configuration of BOMeTyr residues in peptide natural products. Application of this technique to papuamide B (2) revealed the presence of (R)- $\beta$ OMe-D-Tyr in 2, which is epimeric at C $\alpha$  to the corresponding residue in 1. The stereochemical divergence of the  $\beta$ OMeTyr residues in 1 and 2 is somewhat surprising considering the structural similarities and comparable inhibitory activity against HIV for these two peptides. However, this finding is consistent with the observation that the  $\beta$ OMeTyr C $\beta$  proton in 1 is a broadened singlet at  $\delta$ 5.03 while the same proton in 2 appears as a 9.3 Hz doublet at  $\delta$ 4.24. The differing stereochemistry at C $\alpha$  suggests that during biosynthesis of **1** and **2** the  $\beta$ OMeTyr residues arise from incorporation of L-Tyr and D-Tyr, respectively, while the oxidative modification at CB occurs with conserved stereochemistry regardless of the configuration at  $C\alpha$ . Assignment of the complete absolute stereochemistry of neamphamide A (1) and the  $\beta$ OMeTyr residue in papuamide B (2) should now simplify the efforts required to synthesize these peptides. In addition, the method developed for analyzing the  $\beta$ OMeTyr

residues should be applicable to other naturally occurring peptides that contain this amino acid derivative.

#### **Experimental Section**

**GC-MS analysis.** Chiral GC-MS analyses were executed with an Agilent 6890 Series/5973N gas chromatograph-mass selective detector system equipped with a Varian Chirasil-L-Val capillary column (25 m × 0.25 mm i.d., 0.16 µm film thickness), using helium as a carrier gas at a linear velocity of 29.2 cm/s. Temperatures were set to 250 °C at the injection port and 220 °C at the transfer line to the detector. Samples were injected splitless and chromatographed under the oven temperature program of 60 °C for 3 min, 5°C/min heat ramp to 200 °C, and the same temperature held for 10 min. Electron-impact ionization at 70 eV was employed for mass spectral detection and elution of *N*-TFA-OMeAsp dimethyl ester (**16**) was traced by diagnostic fragment ions at m/z 196 and m/z 103.

Conversion of BOMeTyr (5) into N-TFA-OMeAsp Dimethyl Ester (16). A solution of each deprotected amino acid standard (100  $\mu$ g) in a mixture of MeCN (40  $\mu$ L) and H<sub>2</sub>O (30  $\mu$ L) was stirred with  $NaIO_4(2.4 \text{ mg})$  until the salt crystals disappeared. To this solution was added  $CCl_4(40 \ \mu L)$  and a 1mg/mL solution of RuCl<sub>3</sub>hydrate in 0.1 N sodium phosphate buffer (30  $\mu$ L, pH 7.6) and the biphasic mixture was vigorously stirred at room temperature for 16 h. After removal of the solvent, a half portion of the oxidation product was reacted with CbzCl (20  $\mu$ L) in a mixture of 1N KOH (50  $\mu$ L) and freshly distilled 1,4-dioxane (50  $\mu$ L). After stirring for an hour at ambient temperature, 100 µL of 1N KOH was added to the reaction mixture and the unreacted reagent was extracted with EtOAc (100  $\mu$ L  $\times$  3). The aqueous layer was then acidified with 2 N HCl (150  $\mu$ L) and extracted again with EtOAc (100  $\mu$ L  $\times$  5), which yielded N-Cbz-OMeAsp. This material was further esterified with TMS-diazomethane (10 µL, 2M solution in n-hexane) in MeOH (50 µL) by stirring the reaction mixture for 1 h to give N-Cbz-OMeAsp dimethyl ester (15), followed by deprotection of the N-Cbz group by hydrogenolysis on 20% Pd(OH)<sub>2</sub>on carbon (1 mg suspension in 100 µL 4.4% HCOOH in MeOH) under a H<sub>2</sub>atmosphere at room temperature for 4 h. The glass-wool filtrate of the reaction suspension was concentrated and again methylated with 1.25 M HCl in MeOH (100 µL) at 110 °C for 20 min, followed by TFA-amidation with dichloromethane/TFA anhydride (1:1, 100  $\mu$ L) at the same temperature for 5 min to give N-TFA- OMeAsp dimethyl ester (16). The derivatization product was dissolved in MeCN (15  $\mu$ L) and a 1  $\mu$ L aliquot was subjected to GC-MS analysis. Retention times (min): 15.5 for (2R,3R)-, 15.8 for (2S,3S)-, 16.4 for (2R,3S)-, and 16.7 for (2S, 3R)-16.

Analysis of the  $\beta$ OMeTyr Residues in Neamphamide A (1) and Papuamide B (2). A 200µg portion of each peptide was oxidized with RuCl<sub>3</sub>/NaIO<sub>4</sub>as described in the previous section. The dried reaction mixture was dissolved in 1% MeOH in H<sub>2</sub>O, applied to a short column of reversed-phase polymer (PolysorbTM MP-1, 100 mg), and desalted by washing with the same alcoholic water mixture. The peptide was recovered from the column by elution with MeOH and then hydrolyzed in degassed 6 N HCl (200 µL) at 110 °C for 6 h. Half of the hydrolysate was derivatized with HCl-MeOH followed by dichloromethane/TFA anhydride as described above, and a 1 µL aliquot of the product dissolved in MeCN (33 µL) was subjected to GC-MS analysis. Retention times (min): 15.8 for *N*-TFA-OMeAsp dimethyl ester (16) from 1 and 16.4 for 16 from 2.

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

#### Acknowledgements

ACKNOWLEDGMENT. We thank Prof. M. V. D'Auria at Univ. Napoli "Federico II" for helpful discussions. M. A. L. gratefully acknowledges the financial support of the National Institutes of Health (AI-50888). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government.


#### **References and Notes**

- Oku N, Gustafson KR, Cartner LK, Wilson JA, Shigematsu N, Hess S, Pannell LK, Boyd MR, McMahon JB. J. Nat. Prod 2004;67:1407–1411. [PubMed: 15332865]
- (2). (a) Zampella A, D'Auria MV, Paloma LG, Casapullo A, Minale L, Debitus C, Henin Y. J. Am. Chem. Soc 1996;118:6202–6209. (b) D'Auria MV, Zampella A, Paloma LG, Minale L, Debitus C, Roussakis C, Le Bert V. Tetrahedron 1996;52:9589–9596. (c) Zampella A, Randazzo A, Borbone N, Luciani S, Trevisi L, Debitus C, D'Auria MV. Tetrahedron Lett 2002;43:6163–6166.
- (3). Ford PW, Gustafson KR, McKee TC, Shigematsu N, Maurizi LK, Pannell LK, Williams DE, de Silva ED, Lassota P, Allen TM, Van Soest R, Andersen RJ, Boyd MR. J. Am. Chem. Soc 1999;121:5899–5909.
- (4). Trevisi L, Bova S, Cargnelli G, Danieli-Betto D, Floreani M, Germinario E, D'Auria MV, Luciani S. Biochem. Biophys. Res. Comm 2000;279:219–222. [PubMed: 11112442] (b) Trevisi L, Cargnelli G, Ceolotto G, Papparella I, Semplicini A, Zampella A, D'Auria MV, Luciani S. Biochem. Pharmacol 2004;68:1331–1338. [PubMed: 15345322]
- (5). (a) Liang B, Carroll PJ, Joullie MM. Org. Lett 2000;2:4157–4160. [PubMed: 11150188] (b) Okamoto N, Hara O, Makino K, Hamada Y. Tetrahedron: Asymmetry 2001;12:1353–1358. (c) Acevedo CM, Kogut EF, Lipton MA. Tetrahedron 2001;57:6353–6359. [PubMed: 18159221]
- (6). Thoen JC, Morales-Ramos ÁI, Lipton MA. Org. Lett 2002;4:4455–4458. [PubMed: 12465911]
- (7). (a) Guerlavais V, Carroll PJ, Joullie MM. Tetrahedron: Asymmetry 2002;13:675–680. (b) Zampella A, Sorgente M, D'Auria MV. Tetrahedron: Asymmetry 2002;13:681–685. (c) Zampella A, D'Auria MV. Tetrahedron: Asymmetry 2002;13:1237–1239. (d) Turk JA, Visbal GS, Lipton MA. J. Org. Chem 2003;68:7841–7844. [PubMed: 14510564]
- (8). (a) Okamoto N, Hara O, Makino K, Hamada Y. J. Org. Chem 2002;67:9210–9215. [PubMed: 12492322] (b) Hansen DB, Wan X, Carroll PJ, Joullie MM. J. Org. Chem 2005;70:3120. [PubMed: 15822973]
- (9). Marphy P. Carlsberg Res. Comm 1984;49:591-596.
- (10). In ref.1(a), the authors reported a molecular ion of Agdha at m/z 252 and attributed the increase of 17 mu to the formation of an NH<sub>3</sub>adduct. Although it was not mentioned if CD<sub>3</sub>OD was used in NMR experiments prior to the mass measurement, it is possible that the mass observed was the molecular ion of 16.
- (11). Meyers AI, Lawson JP. Tetrahedron Lett 1982;23:4883-4886.
- (12). Hardy PM. Synthesis 1978:290-291.
- (13). Huang Y, Dalton D, Carroll PJ. J. Org. Chem 1997;62:372-376. [PubMed: 11671412]
- (14). Nagai N, Kusumi T. Tetrahedron Lett 1995;36:1853-1856.
- (15). Boger DL, Zhou J, Borzilleri RM, Nukui S, Castle SL. J. Org. Chem 1997;62:2054–2069. [PubMed: 11671510]
- (16). Schöllkopf U, Groth U, Deng C. Angew. Chem. Int. Ed 1981;20:798-799.
- (17). Oxidation without using a buffered solution did not give OMeAsp.
- (18). In a preliminary GC-MS experiment using D- and L-N-Cbz-Asp dimethyl esters as the models, both compounds eluted approximately 5 min after the thermal gradient reached the maximum temperature limit of the Chirasil column (200°C) with poor mutual separation. This suggested that other derivatization of the amino group instead of Cbz was required to improve the chromatographic

Oku et al.

#### behavior of the methylated OMeAsp derivatives.

**NIH-PA Author Manuscript** 



Structure of neamphamide A (1), papuamide B (2), Agdha (3), Htmha (4), and βOMeTyr (5).



#### Scheme 1.

<sup>a</sup>Reagents and conditions: (a) 6 N HCl, 107 °C, 18.5 h; (b) solvent partitioning, 6 N HCl/EtOAc; (c) CD<sub>3</sub>OD, 65 h; (d) PPTS, 2,2-dimethoxypropane, DMF, 45 °C (30 min) -> 60 °C (1.5 h); (e) 2 N HCl in MeOH,60 °C, 15.5 h; (f) H O, reflux, 60 h. <sup>*b*</sup> <sup>b</sup>Data reproduced from ref. 55.



Chart 2. Structure of callipeltin A (9).



#### Scheme 2.

<sup>a</sup>Reagents and conditions: (a) BuLi, 4-BnPhCHO, THF, -30 °C, 3 h; (b) NaI, CH<sub>3</sub>I, THF, 0 ° C, 3 h; (c) 0.25 N HCl, THF-MeCN, 25 °C, 16 h; (d) Ti(O*i*-Pr)<sub>4</sub>, allyl alcohol, 25 °C, 24 h; (e) 0.2 N LiOH-MeOH, rt, 2 days; (f) H<sub>2</sub>, Pd(OH)<sub>2</sub>/C, MeOH-4.4% HCOOH, rt, 4 h.



Scheme 3.


Oku et al.



#### Scheme 4.

<sup>a</sup>Reagents and conditions: (a) RuCl<sub>3</sub>, NaIO<sub>4</sub>, CCl<sub>4</sub>-MeCN-0.1 M sodium phosphate buffer=2:2:3, pH 7.6, rt, 16 h; (b) CbzCl, 1,4-dioxane-1 N KOH, rt, 1h; (c) TMS-diazomethane, MeOH, rt, 1 h; (d) Pd(OH)<sub>2</sub>, 4.4% HCOOH in MeOH, H<sub>2</sub>, rt, 4 h; (e) 1.25 M HCl in MeOH, 110 °C, 30 min; (f) TFAA, dichloromethane, 110 °C, 5 min.

Oku et al.



**Figure 1.** Fragmentation and the typical EI-MS spectrum of *N*-TFA-OMeAsp dimethyl ester (16).